nology, and neuro-oncology. Each issue is intended to serve as a critical reference work in its field. Second, last January Elsevier took over as publisher and began a campaign to enhance the visibility and readership of the journal. In addition, the accessibility of the journal has increased, as it is now available through ScienceDirect, Elsevier's digital journals archive.
Third, during the past year the advocacy community has become more actively involved in ASENT activities and the society has emphasized its commitment to enhancing educational activities for this important constituency. Neurotherapeutics will serve an important role in this mission. Similarly, the journal will support the commitment of ASENT leadership to promote the training of clinician investigators, which includes a didactic training program to be offered in association with the March 2007 annual meeting in Washington, D.C. Collectively these actions are intended to promote the mission of ASENT to facilitate the development of more effective neurotherapeutic drugs and devices.
